- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04691687
OUTpatient Intravenous LASix Trial in Reducing Hospitalization for Acute Decompensated Heart Failure (OUTLAST)
December 29, 2020 updated by: Dr John Heitner, New York Presbyterian Brooklyn Methodist Hospital
OUTpatient Intravenous LASix Trial in Reducing Hospitalization for ADHF (OUTLAST)
Single-center, prospective double-blinded randomized control trial to evaluate the the feasibility, efficacy and safety of outpatient IV diuretic therapy in treatment of heart failure.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Patients were randomized by a clinical pharmacist with the ratio of 1:1:1 into 3 groups: standard of care control arm (Group 1), IV placebo infusion (Group 2), and IV furosemide infusion (Group 3).Patients in Group 2 and 3 received a comprehensive Heart Failure (HF)-care protocol that included bi-weekly clinic visits for dose-adjusted IV-diuretics, medication adjustment and education.
Patients, nurses and treating physicians were blinded to the randomization.
Patients in Group 1 received standard of care treatment per heart failure guidelines at the discretion of the primary cardiologist involved in the patient's care.8
Patients in Group 2 received IV saline infusion (20-40 ml) concentrated by the pharmacist to minimize fluid intake.
Patients in Group 3 received IV furosemide calculated by the pharmacist to be equivalent or higher in dose compared to the patient's home oral dose.
The dose assignments were categorized into low dose (20 mg bolus with 20 mg/hour infusion sessions and 2 ml saline), intermediate dose (40 mg bolus with 40 mg/hour infusion sessions and 4 ml saline) and high dose (80 mg bolus with 80 mg/hour infusion sessions).
The infusions were continuous over 3 hours, biweekly over a one-month period.
Infusions were held at the discretion of the physician utilizing a written protocol (creatinine 25% above baseline, Systolic Blood Pressure(SBP) <80 mmHg or symptoms of presyncope).
Patients in both Groups 2 and 3 resumed all of their oral home medications for HF post infusion visits per standard of care.
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients being admitted with ADHF over 18 years old
- Known history of systolic or diastolic dysfunction of greater than 6 weeks
- NYHA Class II-IV
- Heart failure as defined in [Table 1]. One symptom must be present at time of screening and one sign must be present in the last 12 months
- Elevated pro-BNP >/= 360 pg/ml and not explained by any other etiology
- Willing to consent and comply with scheduled visits and phone calls
Table 1. Criteria for Diagnosing Heart Failure
SYMPTOMS (at least 1 must be present at time of screening):
- Paroxysmal nocturnal dyspnea
- Orthopnea
- Dyspnea on mild or moderate exertion
SIGNS (at least 1 must be present in the last 12 months)
- Any rales post cough
- Jugular venous pressure >/= 10 cm H20
- Lower extremity edema
- Chest X-Ray (CXR) demonstrating pleural effusion, pulmonary congestion, or cardiomegaly
Exclusion Criteria:
- Systolic blood pressure <85 mmHg
- Signs of significant respiratory distress, according to the discretion of the investigator.
- Biventricular Implantable Cardioverter-Defibrillator(ICD) placement within 15 days, cardiogenic shock or volume depletion
- Chronic dialysis
- Acute renal failure defined as creatinine > 2 x baseline
- Severe systemic illness with life expectancy judged less than three years
- Chronic pulmonary disease requiring home O2, oral steroid therapy or hospitalization for exacerbation within 12 months, or significant chronic pulmonary disease in the opinion of the investigator
- Primary hemodynamically significant uncorrected valvular heart disease, obstructive, or regurgitant, or any valvular disease expected to lead to surgery during the trial.
- Atrial fibrillation with resting heart rate >90 bpm
- Myocardial infarction in past 90 days
- Percutaneous coronary intervention in past 30 days
- Heart transplant recipient or currently implanted left ventricular assist device
- Stroke in past 90 days
- No acute infection especially requiring IV antibiotics
- Allergy to Lasix
- Known chronic hepatic disease, defined as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels > 3.0 times the upper limit of normal
- Non-verbal patients, patients who cannot speak or understand English, patients with dementia and psychiatric illness, patients who are blind or deaf and patients who are transferred to different hospital will be excluded.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Standard of Care (Group 1)
Patients in Group 1 received standard of care treatment per heart failure guidelines at the discretion of the primary cardiologist involved in the patient's care.
|
|
Placebo Comparator: IV Placebo Infusion
Patients in Group 2 received IV saline infusion (20-40 ml) concentrated by the pharmacist to minimize fluid intake.The infusions were continuous over 3 hours, biweekly over a one-month period.
|
IV Placebo comparator
Other Names:
|
Experimental: IV Furosemide Infusion
The dose assignments were categorized into low dose (20 mg bolus with 20 mg/hour infusion sessions and 2 ml saline), intermediate dose (40 mg bolus with 40 mg/hour infusion sessions and 4 ml saline) and high dose (80 mg bolus with 80 mg/hour infusion sessions).
The infusions were continuous over 3 hours, biweekly over a one-month period.Infusions were held at the discretion of the physician utilizing a written protocol (creatinine 25% above baseline, SBP <80 mmHg or symptoms of presyncope).
|
IV loop diuretic therapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Re-hospitalization for Heart Failure
Time Frame: 30 days
|
30-day rehospitalization for Heart Failure
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Kansas City Cardiomyopathy Questionnaire(KCCQ) outcome measures
Time Frame: Change from Baseline to 30 days
|
Change in Quality of life will be quantified using KCCQ questionnaires
|
Change from Baseline to 30 days
|
Death, Myocardial Infarction, Stroke
Time Frame: 30 days, 180 days
|
Occurrence of death, myocardial infarction, or stroke
|
30 days, 180 days
|
PHQ-2 outcome measures
Time Frame: Change from Baseline to 30 days
|
Change in depressive symptoms will be quantified using PHQ-2 questionnaire
|
Change from Baseline to 30 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
New York Heart Association (NYHA) Class
Time Frame: Baseline and 30 days
|
Change in NYHA functional class
|
Baseline and 30 days
|
LV function
Time Frame: Baseline and 30 days
|
Echo will be performed to evaluate heart function
|
Baseline and 30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2012
Primary Completion (Actual)
December 22, 2017
Study Completion (Actual)
December 22, 2017
Study Registration Dates
First Submitted
December 23, 2020
First Submitted That Met QC Criteria
December 29, 2020
First Posted (Actual)
December 31, 2020
Study Record Updates
Last Update Posted (Actual)
December 31, 2020
Last Update Submitted That Met QC Criteria
December 29, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 307139 (Other Identifier: New York-Presbyterian Brooklyn Methodist Hospital)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
Clinical Trials on IV Solution
-
Eli Lilly and CompanyCompletedAlzheimer's DiseaseUnited States
-
argenxNot yet recruitingMyositis | Dermatomyositis
-
Aquinox Pharmaceuticals (Canada) Inc.Quotient ClinicalCompletedHealthy VolunteerUnited Kingdom
-
Debiopharm International SACompletedHealthy VolunteersUnited Kingdom
-
NYU Langone HealthNaurex, Inc, an affiliate of Allergan plcWithdrawn
-
King Edward Medical UniversityCompleted
-
Janssen Pharmaceutical K.K.CompletedMycoses | Candidiasis | Neutropenia | Aspergillosis | Cryptococcosis | Histoplasmosis | BlastomycosisJapan
-
MallinckrodtCompletedPostoperative Pain | HysterectomyUnited States
-
Theravance BiopharmaGlaxoSmithKline; Hammersmith Medicines ResearchCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom
-
Boehringer IngelheimCompletedColitis, UlcerativeSpain, United Kingdom, United States, Belgium, Germany, Italy, Austria, Canada, Japan, Korea, Republic of, Russian Federation, Poland